Cocrystal Pharma (NASDAQ:COCP) Stock, Quote.Headers.trade-ideas

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

StockMarket analysts

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

COCP

SNOW

URBN

Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Penny Stocks

Movers

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company completed a $4 million private placement.

Why Cocrystal Pharma Shares Are Trading Higher Today

Small Cap

Intraday Update

AMBO

APLM

AREB

AREN

ARVL

AUDC

BRFH

BTTX

CADL

CLXT

EBIX

ELEV

ELOX

EOSE

GCTK

GFAI

GRVY

JFBR

KSPN

LTRY

MGNX

MICS

MSGM

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

OCTO

ONCS

OUST

PEAR

PLXP

PXMD

SECO

Syneos Health, Inc. - Class A Common Stock

SYNH

TGTX

TRKA

UFAB

VORB

WDFC

Gainers


	PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.


Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Cocrystal Pharma Inc

Alibaba Group Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) is revving up its engines, courtesy of a new partnership with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) that promises to take autonomous driving to <a href="https://www.benzinga.com/quote/BABA/news">the next level</a>.
By integrating Alibaba's Qwen large language models (LLMs) with Nvidia's Drive AGX Orin platform, this collaboration not only enhances in-car AI capabilities but also showcases Alibaba's strategic maneuvering amid U.S. sanctions on advanced semiconductor chips.
In a display of synergy, Alibaba Cloud's partnership with Nvidia aims to enhance the driving experience for smart vehicle owners, equipping cars with intelligent voice assistants capable of executing commands and offering recommendations.
This move positions Alibaba at the forefront of automotive AI technology, ensuring it remains competitive in a rapidly evolving market.
Read Also: <a href="https://www.benzinga.com//node/40977069">Alibaba Teams Up With Nvidia to Supercharge EVs for Chinese Automakers: Report</a>
<h2 class="wp-block-heading">Driving Up Investor Confidence: PBoC&#8217;s Boost Fuels Alibaba</h2>
This tech alliance comes at a fortuitous time as the People's Bank of China (PBoC) recently slashed key interest rates, flooding the banking system with liquidity and sparking a <a href="https://www.benzinga.com/markets/asia/24/09/41003814/chinese-stocks-jump-as-central-bank-unveils-major-stimulus-to-spur-economy-a-step-in-the-right-direc">rally in Chinese stocks.</a>
With the National Day Holiday approaching, investor confidence is rising—making it the perfect backdrop for Alibaba&#8217;s ambitious automotive aspirations.
<h2 class="wp-block-heading">Charting The Course: Buckle Up For Bullish Trends</h2>
Alibaba&#8217;s stock is cruising at about $95, a solid 5.45% increase at the time of publication Tuesday.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085152/Screenshot-2024-09-24-at-5.02.54-PM.png" alt="" class="wp-image-563149" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085152/Screenshot-2024-09-24-at-5.02.54-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085152/Screenshot-2024-09-24-at-5.02.54-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The stock has increased 20.51% year-to-date and 3.29% over the past year, signaling a robust performance in a volatile market.
From a technical standpoint, the charts are painting a picture of bullish momentum. Alibaba stock is currently above its five, 20 and 50-day exponential moving averages, indicating a strongly bullish trend despite experiencing slight selling pressure. 
Here's the breakdown:
<ul>
<li>Eight-Day SMA: $87.41 (Bullish signal)</li>
<li>20-Day SMA: $84.43 (Bullish signal)</li>
<li>50-Day SMA: $81.26 (Bullish signal)</li>
<li>200-Day SMA: $76.52 (Bullish signal)</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085423/Screenshot-2024-09-24-at-5.03.51-PM.png" alt="" class="wp-image-563160" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085423/Screenshot-2024-09-24-at-5.03.51-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24085423/Screenshot-2024-09-24-at-5.03.51-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The Moving Average Convergence Divergence (MACD) currently sits at 1.98, indicating a bullish trend for Alibaba stock.
However, caution is advised as the Relative Strength Index (RSI) reads 69.13, indicating that the stock is about to enter the overbought territory.
The Bollinger Bands also favor a bullish stance, with the stock trading above the upper bullish range.
<h2 class="wp-block-heading">Full Speed Ahead: Signs Point To Opportunity In BABA</h2>
Alibaba's strategic partnership with Nvidia has set the stage for exciting developments in the autonomous driving sector, while the technical indicators suggest a bright future for Alibaba stock. 
As the company prepares for an AI-enhanced driving experience, investors should stay focused on the potential ahead—this journey is just beginning.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/40988975">Alibaba Shares Are Trading Higher: What&#8217;s Going On</a></li>
</ul>
Photo: Shutterstock

Asia

Emerging Markets

Technicals

Tech

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

NVDA

Alibaba Partners With Nvidia To Advance AI, Autonomous Driving, Chart Indicates Positive Momentum

WIIM

Visa shares are trading lower following reports suggesting the company is facing charges by the DOJ for alleged monopolization.

Goldman Sachs analyst Noah Poponak maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and lowers the price target from $232 to $202.

Goldman Sachs Maintains Buy on Boeing, Lowers Price Target to $202

STLD

VALE

Shares of metals and materials companies are trading higher. Strength may be due to China's stimulus measures, which could support demand.

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $29 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $29 Price Target

BNZI

Banzai International Shares Halted On Circuit Breaker To The Upside, Stock Now Up 139.5%

Goldman Sachs analyst Michael Ng maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Buy and raises the price target from $390 to $430.

ANET

Goldman Sachs Maintains Buy on Arista Networks, Raises Price Target to $430

<a href="https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.">https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.</a>
Two Democratic lawmakers are working to preserve health providers' right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction.&nbsp;
A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration's during the Covid-19 pandemic. Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers' new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.&nbsp;&nbsp;
The flexible rules are set to expire at the end of the year, which telehealth advocates say could threaten patient access to medications, including stimulants for ADHD and common medications used to treat opioid addiction.&nbsp;

Biotech

General

TDOC

'Lawmakers Push To Let Telehealth Providers Keep Prescribing Stimulants And Addiction Treatment; Flexibility Allowed During Pandemic Is Set To Expire At Year-End' - STAT News

Investors with a lot of money to spend have taken a bullish stance on Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DIS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Walt Disney.
This isn't normal.
The overall sentiment of these big-money traders is split between 69% bullish and 30%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $435,284, and 6 are calls, for a total amount of $421,675.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $95.0 to $115.0 for Walt Disney over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Walt Disney options trades today is 3726.86 with a total volume of 2,805.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Walt Disney's big money trades within a strike price range of $95.0 to $115.0 over the last 30 days.
<h3>Walt Disney 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727187394_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$11.6</td>
<td>$10.75</td>
<td>$11.45</td>
<td>$110.00</td>
<td>$148.7K</td>
<td>137</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.25</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$105.00</td>
<td>$146.3K</td>
<td>6.2K</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.35</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$105.00</td>
<td>$87.3K</td>
<td>6.2K</td>
<td style="text-align: right;">180</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.2</td>
<td>$13.15</td>
<td>$13.17</td>
<td>$105.00</td>
<td>$84.4K</td>
<td>6.2K</td>
<td style="text-align: right;">192</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.89</td>
<td>$1.88</td>
<td>$1.88</td>
<td>$100.00</td>
<td>$73.1K</td>
<td>9.7K</td>
<td style="text-align: right;">429</td>
</tr>
</tbody>
</table>

<h3>About Walt Disney</h3>
Disney operates in three global business segments: entertainment, sports, and experiences. Entertainment and experiences both benefit from franchises and characters the firm has created over the course of a century. Entertainment includes the ABC broadcast network, several cable television networks, and the Disney+ and Hulu streaming services. Within the segment, Disney also engages in movie and television production and distribution, with content licensed to movie theaters, other content providers, or, increasingly, kept in-house for use on Disney's own streaming platform and television networks. The sports segment houses ESPN and the ESPN+ streaming service. Experiences contains Disney's theme parks and vacation destinations, and also benefits from merchandise licensing.
<h3>Present Market Standing of Walt Disney</h3>
<ul>
<li>With a trading volume of 1,522,167, the price of DIS is down by -0.4%, reaching $92.6.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 43 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Walt Disney</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $91.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Macquarie has decided to maintain their Neutral rating on Walt Disney, which currently sits at a price target of $91. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walt Disney options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Walt Disney Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COST usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Costco Wholesale. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 33% bearish. Among these notable options, 6 are puts, totaling $238,687, and 12 are calls, amounting to $1,132,282.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $675.0 to $1200.0 for Costco Wholesale over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Costco Wholesale's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Costco Wholesale's whale trades within a strike price range from $675.0 to $1200.0 in the last 30 days. 
<h3>Costco Wholesale 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727187389_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$24.0</td>
<td>$23.6</td>
<td>$24.0</td>
<td>$910.00</td>
<td>$480.0K</td>
<td>47</td>
<td style="text-align: right;">201</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$251.2</td>
<td>$248.55</td>
<td>$251.2</td>
<td>$675.00</td>
<td>$175.8K</td>
<td>23</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$29.0</td>
<td>$28.65</td>
<td>$29.0</td>
<td>$900.00</td>
<td>$142.1K</td>
<td>1.0K</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$67.85</td>
<td>$66.5</td>
<td>$66.5</td>
<td>$850.00</td>
<td>$66.5K</td>
<td>241</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$102.8</td>
<td>$100.05</td>
<td>$101.32</td>
<td>$1000.00</td>
<td>$60.7K</td>
<td>28</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and enjoys over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 270 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
After a thorough review of the options trading surrounding Costco Wholesale, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>With a volume of 271,797, the price of COST is down -1.12% at $906.8. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Costco Wholesale</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $919.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $925. 
&#x2A; An analyst from Truist Securities downgraded its action to Hold with a price target of $873. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Costco Wholesale, targeting a price of $925. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $925. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Costco Wholesale, maintaining a target price of $950. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Costco Wholesale options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

COST

Unpacking the Latest Options Trading Trends in Costco Wholesale

EF Hutton analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $10 price target.

ANIX

EF Hutton Maintains Buy on Anixa Biosciences, Maintains $10 Price Target

Whales with a lot of money to spend have taken a noticeably bearish stance on Micron Technology.
Looking at options history for Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) we detected 18 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $654,501 and 13, calls, for a total amount of $503,506.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $115.0 for Micron Technology over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Micron Technology options trades today is 5456.94 with a total volume of 4,561.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Micron Technology's big money trades within a strike price range of $80.0 to $115.0 over the last 30 days.
<h3>Micron Technology Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727187384_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$24.2</td>
<td>$24.1</td>
<td>$24.1</td>
<td>$115.00</td>
<td>$269.9K</td>
<td>4.2K</td>
<td style="text-align: right;">139</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.05</td>
<td>$13.95</td>
<td>$13.95</td>
<td>$100.00</td>
<td>$139.5K</td>
<td>13.5K</td>
<td style="text-align: right;">131</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.15</td>
<td>$13.55</td>
<td>$13.55</td>
<td>$85.00</td>
<td>$135.5K</td>
<td>1.8K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$2.54</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$100.00</td>
<td>$104.7K</td>
<td>18.8K</td>
<td style="text-align: right;">940</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$95.00</td>
<td>$79.5K</td>
<td>3.5K</td>
<td style="text-align: right;">169</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
After a thorough review of the options trading surrounding Micron Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Micron Technology's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,130,753, the MU's price is up by 0.01%, now at $93.58. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Micron Technology</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $123.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Micron Technology with a target price of $175. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Micron Technology, targeting a price of $135. 
&#x2A; Reflecting concerns, an analyst from Exane BNP Paribas lowers its rating to Underperform with a new price target of $67. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Micron Technology with a target price of $100. 
&#x2A; An analyst from Needham persists with their Buy rating on Micron Technology, maintaining a target price of $140. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Micron Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About Micron Technology

Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) will release earnings results for its fourth quarter, after the <a href="https://www.benzinga.com/quote/MU/earnings">closing bell on Wednesday, Sept. 25.</a>
Analysts expect the Boise, Idaho-based company to report quarterly earnings at $1.13 per share, versus a year-ago loss of $1.07 per share. Micron is projected to post quarterly revenue of $7.64 billion, up from $4.01 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 17, Micron announced the availability of the Crucial P310 2280 Gen4 NVMe solid-state drive (SSD) which expands Micron&#8217;s P310 portfolio to address PCs, laptops and PlayStation 5. The company said a version with a heatsink will be released in the coming months, suited for use with PlayStation 5 and desktop gaming PCs.
Micron shares gained 2.9% to close at $93.57 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8cb85e9300015f1add/brian-chin">Stifel analyst Brian Chin</a> maintained a Buy rating and cut the price target from $165 to $135 on Sept. 19. This analyst has an accuracy rate of 70%.</li>
<li>Wells Fargo analyst Aaron Rakers maintained an Overweight rating and cut the price target from $190 to $175 on Sept. 18. This analyst has an accuracy rate of 85%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586bc4bc351b9b0001ab735d/timothy-arcuri">UBS analyst Timothy Arcuri</a> maintained a Buy rating and slashed the price target from $153 to $135 on Sept. 17. This analyst has an accuracy rate of 78%.</li>
<li>Citigroup analyst Christopher Danely maintained a Buy rating and cut the price target from $175 to $150 on Sept. 17. This analyst has an accuracy rate of 79%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58072986846faa000106abc6/joseph-moore">Morgan Stanley analyst Joseph Moore </a>maintained an Equal-Weight rating and decreased the price target from $140 to $100 on Sept. 16. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying MU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24030947/image-179-1024x514.png" alt="" class="wp-image-562446" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24030947/image-179-1024x514.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24030947/image-179-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24030947/image-179-768x385.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24030947/image-179.png 1356w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financials Stocks That May Plunge In September</a></li>
</ul>

Earnings

Micron Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Banzai International Shares Resume Trading

JMP Securities analyst David Scharf reiterates OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) with a Market Outperform and maintains $60 price target.

JMP Securities Reiterates Market Outperform on OneMain Holdings, Maintains $60 Price Target

Luke Gromen, president and founder of research firm Forest For The Trees, warns that the U.S. dollar-centric global monetary system is breaking down but gold and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are <a href="https://www.benzinga.com/money/bitcoin-price-prediction">well-positioned assets</a>.
What Happened: In a recent <a href="https://www.youtube.com/watch?v=Vx4p3X-ZpYs">interview</a>, Gromen argued that the U.S. government&#8217;s fiscal situation has become so precarious that it now requires negative real interest rates and continued stock market gains to remain solvent.
"The reserve currency issuer of the world cannot afford their debt unless real rates are negative over some sustained period of time," Gromen stated. He pointed out that in August, the U.S. government's "true interest expense" &#8211; including entitlements and interest payments &#8211; reached 150% of tax receipts.
Gromen believes this dynamic will force the Federal Reserve to cut interest rates aggressively, regardless of economic conditions.
While skeptical of proposed anti-inflation measures from presidential candidates, Gromen predicts inflation will rebound as the government seeks to inflate away its debt burden. He sees gold and Bitcoin as well-positioned assets in this environment, expecting gold to potentially reach $3,000 per ounce (currently $2,632 per ounce).
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40994964/peter-schiff-isnt-pleased-with-markets-bitcoin-obsession-while-gold-is-touching-record-hig">Peter Schiff Isn&#8217;t Pleased With Market&#8217;s Bitcoin Obsession While Gold Is Touching Record Highs: &#8216;Few Investors Notice Or Care&#8217;</a>
Why It Matters: Gromen expressed optimism about Bitcoin&#8217;s prospects alongside gold in the current economic environment.
He suggested that Bitcoin has likely attracted some investment that might have previously gone to gold mining stocks, noting, &#8220;Some portion of people that buy gold miners have historically been &#8216;Well, I want to own gold, but I want to own gold with a ticker.'&#8221;
He added that the narrative for these investors may be to buy Bitcoin if they want to own gold &#8220;with a leverage.&#8221; Gromen sees both gold and Bitcoin as well-positioned assets in a regime where the world&#8217;s most indebted nation requires negative real interest rates to service its debt.
"If stocks go down and stay down, the U.S. receipts will not cover true interest expense," Gromen cautioned, underscoring the government&#8217;s dependence on rising asset prices to fund its operations. He believes U.S. stocks must continue rising to drive consumer spending and tax receipts, making a major market correction unlikely.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40858231/bitcoin-decouples-from-gold-investors-leaning-towards-traditional-safe-haven-assets-crypto">Bitcoin Decouples From Gold: &#8216;Investors Leaning Towards Traditional Safe-Haven Assets,&#8217; CryptoQuant Signals</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Is 'Gold With A Leverage,' Says Expert Who Sees US Government In Big Trouble Over Debt Burden

EF Hutton analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

ENLV

EF Hutton Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Banzai International Shares Halted On Circuit Breaker To The Upside, Stock Now Up 100.5%

JMP Securities analyst Joey Marincek reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Market Outperform and maintains $30 price target.

JAMF

JMP Securities Reiterates Market Outperform on Jamf Holding, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $40 price target.

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price ...

Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)

An update from Cocrystal Pharma (COCP) is now available. Cocrystal Pharma, Inc. recently shared exciting news about their CC-42344 product candidat...

Cocrystal Pharma's Promising Antiviral Candidate for Influenza A

Noble Financial Sticks to Its Buy Rating for Cocrystal Pharma (COCP)

Cocrystal Pharma (COCP) Receives a Buy from Noble Financial

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cocrystal Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/cocp-stock-quote/">COCP</a>) just reported results for the second quarter of 2024.<ul><li>Cocrystal Pharma reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -48 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cocp-stock-earnings-cocrystal-pharma-for-q2-of-2024/">COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024

Cocrystal Pharma GAAP EPS of -$0.53 misses by $0.03

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and IGM Bi...

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and IGM Biosciences (IGMS)

Cocrystal Pharma (COCP) has issued an update. Cocrystal Pharma, Inc. has announced its plans to participate in upcoming investment conferences, sig...

Cocrystal Pharma Engages Investors at Upcoming Conferences

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price t...

Buy Rating Affirmed for Cocrystal Pharma Amid Promising Drug Pipeline and Strong Clinical Results

AMAT

ASTS

ASXC

ATOS

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

CSCO

CTRM

ESPR

GLNG

GOEV

GOLD

GRAB

HUYA

IGMS

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

NNDM

OGEN

PSFE

RRAC

SACH

STNE

TAYD

TCEHY

TCRT

VUZI

WKHS

XXII

Press Releases

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Events

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Cocrystal Pharma

Cocrystal Pharma (COCP) Forecast

Cocrystal Pharma (NASDAQ:COCP) Stock, Quote.Headers.trade-ideas